Lacto-N-neohexaose (LNnH) is getting more and more attention in the fields of medicine, food, and life sciences. CD BioGlyco provides high-quality production services of LNnH, our years of experience and expertise have won us praise from clients all over the world.
Human milk oligosaccharides (HMOs) are complex glycans that are abundant in human milk. The core structure of HMO can be fucosylated and/or sialylated. For most HMOs, in addition to prebiotic effects, their exact biological mechanism of action still needs to be explored. LNnH, as a branched hexasaccharide, has potential relevance with many beneficial health effects. As shown in Figure 1, the lactose disaccharide at the reduced end of LNnH is very common in the HMO structure. At C-3 and C-6, it is extended by N-acetyllactosamine disaccharides.
Fig.1 Structure of LNnH. (Bandara, et al., 2020)
LNnH was first isolated and characterized from human milk by Kobata and Ginsburg in 1972. Through this isolation and identification, some fucosyl and sialic acid derivatives of LNnH were also found in human milk. In many separation reports, the majority of oligosaccharides in the milk of many carnivores (such as Urvidae, seals, Elephas maximus, etc.) are lactose-N-neotetraose or LNnH as the core unit. In light of this, it is speculated that LNnH may play a significant role in their life activities. In addition, the early contact of LNnH derivatives regulates the adhesion of bifidobacteria for infants, and the utilization of carbohydrates will become more important after the bacteria temporarily settle in the host cells in a sufficient number. This provides a certain reference value for the development of new infant formula.
CD BioGlyco provides separation and purification, chemical, enzymatic, metabolic engineering, and chemoenzymatic methods to produce LNnH. The Optimization Technologies we accumulate include but are not limited to the following:
Various high-grade standards and fully optimized separation routes.
Deeply optimizing the reaction conditions and donor-receptor combination.
Efficiently promoting the glycosylation reaction.
Selection and identification of suitable enzymes.
Optimal enzyme expression levels.
A complete and mature service product line from strain development to mass manufacturing.
Protein engineering, metabolic engineering, and synthetic biology strategies and tools.
CD BioGlyco is a leader in human milk oligosaccharides research, and we are looking forward to being your research assistant in the production of LNnH. If you are interested in our services, please feel free to contact us.
Reference
